found: Work cat.: Stevenson, M. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women, c2007:p. 12 (strontium ranelate is composed of two atoms of stable strontium and one molecule of ranelic acid; it is marketed in the UK as Protelos Strontium ranelate is a patented form of strontium that is well studied and currently approved for the treatment of osteoporosis in most of Europe but not yet approved in the United States.)
found: About Osteoporosis web site, 3 May 2007:treatments (Strontium ranelate is marketed as a medicinal product by the French company Servier under the brand name Protelos)
found: BMJ web site, 3 May 2007:comment, BMJ 2005 June 18, editorial (strontium ranelate is composed of two atoms of stable strontium combined with organic ranelic acid; it seems to have a unique effect in that it inhibits bone resorption as well as stimulating bone formation)
found: MeSH browser, Oct. 3, 2007MeSH suppl. concept data (strontium ranelate. Entry terms: 3-(3-cyano-4-carboxymethyl-5-carboxy-2-thienyl)-3-azapentanedioic distrontium salt; protelos. Headings mapped to: Organometallic compounds; Thiophenes)
